{
  "gold_standard": {
    "pancreatic_cancer_advanced": {
      "expected_extraction": {
        "entities": [
          {
            "text": "FOLFIRINOX",
            "type": "treatment",
            "start_char": 0,
            "end_char": 10
          },
          {
            "text": "Gemcitabine",
            "type": "treatment",
            "start_char": 14,
            "end_char": 25
          },
          {
            "text": "Nab-Paclitaxel",
            "type": "treatment",
            "start_char": 26,
            "end_char": 40
          },
          {
            "text": "metastatic pancreatic adenocarcinoma",
            "type": "condition",
            "start_char": 90,
            "end_char": 125
          }
        ]
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "text": "FOLFIRINOX",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "Gemcitabine",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "Nab-Paclitaxel",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "metastatic pancreatic adenocarcinoma",
            "mcode_type": "CancerCondition",
            "confidence": 0.95
          }
        ]
      }
    },
    "ovarian_cancer_recurrent": {
      "expected_extraction": {
        "entities": [
          {
            "text": "PARP Inhibitor",
            "type": "treatment",
            "start_char": 0,
            "end_char": 14
          },
          {
            "text": "platinum-based chemotherapy",
            "type": "treatment",
            "start_char": 80,
            "end_char": 105
          },
          {
            "text": "platinum-sensitive recurrent ovarian cancer",
            "type": "condition",
            "start_char": 45,
            "end_char": 85
          }
        ]
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "text": "PARP Inhibitor",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "platinum-based chemotherapy",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.85
          },
          {
            "text": "platinum-sensitive recurrent ovarian cancer",
            "mcode_type": "CancerCondition",
            "confidence": 0.95
          }
        ]
      }
    },
    "glioblastoma_newly_diagnosed": {
      "expected_extraction": {
        "entities": [
          {
            "text": "TTFields",
            "type": "treatment",
            "start_char": 0,
            "end_char": 8
          },
          {
            "text": "Temozolomide",
            "type": "treatment",
            "start_char": 14,
            "end_char": 26
          },
          {
            "text": "newly diagnosed glioblastoma",
            "type": "condition",
            "start_char": 50,
            "end_char": 75
          }
        ]
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "text": "TTFields",
            "mcode_type": "Radiotherapy",
            "confidence": 0.8
          },
          {
            "text": "Temozolomide",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "newly diagnosed glioblastoma",
            "mcode_type": "CancerCondition",
            "confidence": 0.95
          }
        ]
      }
    },
    "bladder_cancer_muscle_invasive": {
      "expected_extraction": {
        "entities": [
          {
            "text": "Immunotherapy",
            "type": "treatment",
            "start_char": 0,
            "end_char": 13
          },
          {
            "text": "anti-PD-L1 antibody",
            "type": "treatment",
            "start_char": 18,
            "end_char": 36
          },
          {
            "text": "chemotherapy",
            "type": "treatment",
            "start_char": 41,
            "end_char": 53
          },
          {
            "text": "muscle-invasive bladder cancer",
            "type": "condition",
            "start_char": 60,
            "end_char": 88
          }
        ]
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "text": "Immunotherapy",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.85
          },
          {
            "text": "anti-PD-L1 antibody",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "chemotherapy",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "muscle-invasive bladder cancer",
            "mcode_type": "CancerCondition",
            "confidence": 0.95
          }
        ]
      }
    },
    "multiple_myeloma_relapsed": {
      "expected_extraction": {
        "entities": [
          {
            "text": "CAR-T Cell Therapy",
            "type": "treatment",
            "start_char": 0,
            "end_char": 18
          },
          {
            "text": "BCMA-directed CAR-T cells",
            "type": "treatment",
            "start_char": 25,
            "end_char": 49
          },
          {
            "text": "triple-class refractory multiple myeloma",
            "type": "condition",
            "start_char": 70,
            "end_char": 107
          }
        ]
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "text": "CAR-T Cell Therapy",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "BCMA-directed CAR-T cells",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "triple-class refractory multiple myeloma",
            "mcode_type": "CancerCondition",
            "confidence": 0.95
          }
        ]
      }
    },
    "head_neck_cancer_recurrent": {
      "expected_extraction": {
        "entities": [
          {
            "text": "Anti-PD-1",
            "type": "treatment",
            "start_char": 0,
            "end_char": 9
          },
          {
            "text": "Cetuximab",
            "type": "treatment",
            "start_char": 14,
            "end_char": 23
          },
          {
            "text": "platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma",
            "type": "condition",
            "start_char": 50,
            "end_char": 120
          }
        ]
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "text": "Anti-PD-1",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "Cetuximab",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma",
            "mcode_type": "CancerCondition",
            "confidence": 0.95
          }
        ]
      }
    },
    "gastric_cancer_advanced": {
      "expected_extraction": {
        "entities": [
          {
            "text": "Immunotherapy",
            "type": "treatment",
            "start_char": 0,
            "end_char": 13
          },
          {
            "text": "Anti-PD-1 antibody",
            "type": "treatment",
            "start_char": 18,
            "end_char": 35
          },
          {
            "text": "chemotherapy",
            "type": "treatment",
            "start_char": 41,
            "end_char": 53
          },
          {
            "text": "advanced gastric or gastroesophageal junction adenocarcinoma",
            "type": "condition",
            "start_char": 80,
            "end_char": 140
          }
        ]
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "text": "Immunotherapy",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.85
          },
          {
            "text": "Anti-PD-1 antibody",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "chemotherapy",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "advanced gastric or gastroesophageal junction adenocarcinoma",
            "mcode_type": "CancerCondition",
            "confidence": 0.95
          }
        ]
      }
    },
    "renal_cell_carcinoma_advanced": {
      "expected_extraction": {
        "entities": [
          {
            "text": "IO/TKI Combination",
            "type": "treatment",
            "start_char": 0,
            "end_char": 18
          },
          {
            "text": "Immunotherapy",
            "type": "treatment",
            "start_char": 19,
            "end_char": 32
          },
          {
            "text": "Tyrosine Kinase Inhibitor",
            "type": "treatment",
            "start_char": 37,
            "end_char": 61
          },
          {
            "text": "Sunitinib",
            "type": "treatment",
            "start_char": 65,
            "end_char": 74
          },
          {
            "text": "advanced renal cell carcinoma",
            "type": "condition",
            "start_char": 100,
            "end_char": 128
          }
        ]
      },
      "expected_mcode_mappings": {
        "mapped_elements": [
          {
            "text": "IO/TKI Combination",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.85
          },
          {
            "text": "Immunotherapy",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.85
          },
          {
            "text": "Tyrosine Kinase Inhibitor",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "Sunitinib",
            "mcode_type": "CancerRelatedMedicationAdministration",
            "confidence": 0.9
          },
          {
            "text": "advanced renal cell carcinoma",
            "mcode_type": "CancerCondition",
            "confidence": 0.95
          }
        ]
      }
    }
  }
}